TapImmune appoints David Laskow-Pooley to board
This article was originally published in Scrip
TapImmune, an immunotherapy company specializing in the development of therapies for cancer and infectious disease, has appointed David Laskow-Pooley to its board of directors. Mr Laskow-Pooley is currently CEO of London Pharma, a clinical-stage company re-purposing approved drugs through novel drug delivery technologies, and is the co-founder of Pharmafor. He was formerly managing director (UK) of Nasdaq-listed drug discovery platform company, OSI, and was part of the corporate team that developed and launched Tarceva for the treatment of lung cancer with marketing partners Roche and Genentech.